GH Stock Income Statements
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Quarterly Income Statements
Quarterly
|
Annual
Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue: | |||||||||||||||||||||||
precision oncology testing | 156,229,000 | 142,189,000 | 133,423,000 | 125,244,000 | 113,393,000 | 113,797,000 | 102,054,000 | 92,062,000 | 84,136,000 | 88,707,000 | 79,272,000 | 72,604,000 | 63,729,000 | 64,703,000 | 60,384,000 | 50,991,000 | 60,246,000 | 57,414,000 | 52,147,000 | 42,064,000 | 28,837,000 | 28,096,000 | 18,298,000 |
development services and other | 12,262,000 | 12,865,000 | 9,607,000 | 11,906,000 | 15,321,000 | 13,094,000 | 15,350,000 | 17,082,000 | 11,963,000 | 19,401,000 | 15,507,000 | 19,497,000 | 14,936,000 | 13,613,000 | 14,185,000 | ||||||||
total revenue | 168,491,000 | 155,054,000 | 143,030,000 | 137,150,000 | 128,714,000 | 126,891,000 | 117,404,000 | 109,144,000 | 96,099,000 | 108,108,000 | 94,779,000 | 92,101,000 | 78,665,000 | 78,316,000 | 74,569,000 | 66,335,000 | 67,510,000 | 62,897,000 | 60,848,000 | 53,975,000 | 36,655,000 | 32,873,000 | 21,692,000 |
yoy | 30.90% | 22.19% | 21.83% | 25.66% | 33.94% | 17.37% | 23.87% | 18.50% | 22.16% | 38.04% | 27.10% | 38.84% | 16.52% | 24.51% | 22.55% | 22.90% | 84.18% | 91.33% | 180.51% | ||||
qoq | 8.67% | 8.41% | 4.29% | 6.55% | 1.44% | 8.08% | 7.57% | 13.57% | -11.11% | 14.06% | 2.91% | 17.08% | 0.45% | 5.02% | 12.41% | -1.74% | 7.33% | 3.37% | 12.73% | 47.25% | 11.50% | 51.54% | |
costs and operating expenses: | |||||||||||||||||||||||
cost of precision oncology testing | 59,306,000 | 57,417,000 | 53,648,000 | 49,357,000 | 45,106,000 | 43,706,000 | 39,434,000 | 34,375,000 | 30,684,000 | 32,254,000 | 29,665,000 | 24,887,000 | 23,590,000 | 22,070,000 | 16,699,000 | 17,809,000 | 18,191,000 | 20,004,000 | 16,578,000 | 14,650,000 | 11,023,000 | 12,624,000 | 9,671,000 |
cost of development services and other | 5,990,000 | 5,100,000 | 3,966,000 | 4,491,000 | 7,967,000 | 3,415,000 | 1,062,000 | 2,352,000 | 1,297,000 | 1,168,000 | 1,151,000 | 5,040,000 | 5,157,000 | 6,337,000 | 4,488,000 | ||||||||
research and development expense | 83,802,000 | 89,856,000 | 93,851,000 | 90,359,000 | 93,128,000 | 106,578,000 | 100,017,000 | 85,455,000 | 81,757,000 | 73,021,000 | 70,968,000 | 63,724,000 | 55,508,000 | 40,282,000 | 36,245,000 | 36,319,000 | 37,016,000 | 25,875,000 | 24,569,000 | 19,532,000 | 16,316,000 | 16,652,000 | 14,253,000 |
sales and marketing expense | 80,425,000 | 79,127,000 | 68,934,000 | 71,043,000 | 76,123,000 | 81,423,000 | 80,370,000 | 73,603,000 | 64,432,000 | 59,599,000 | 50,228,000 | 47,716,000 | 34,338,000 | 31,288,000 | 25,095,000 | 25,015,000 | 25,115,000 | 22,287,000 | 18,802,000 | 19,439,000 | 17,807,000 | 17,114,000 | 13,464,000 |
general and administrative expense | 38,651,000 | 37,665,000 | 36,174,000 | 41,516,000 | 40,445,000 | 37,888,000 | 41,121,000 | 43,680,000 | 41,267,000 | 40,274,000 | 50,055,000 | 48,376,000 | 67,935,000 | 69,505,000 | 66,294,000 | 37,186,000 | 19,785,000 | 18,859,000 | 16,440,000 | 13,439,000 | 12,661,000 | 12,547,000 | 8,129,000 |
total costs and operating expenses | 268,174,000 | 352,565,000 | 256,573,000 | 256,766,000 | 262,769,000 | 273,010,000 | 262,004,000 | 239,465,000 | 219,437,000 | 206,316,000 | 202,067,000 | 189,743,000 | 186,528,000 | 169,482,000 | 148,821,000 | 120,955,000 | 102,422,000 | 88,859,000 | 78,325,000 | 69,243,000 | 60,319,000 | 60,260,000 | 45,897,000 |
income from operations | -99,683,000 | -197,511,000 | -113,543,000 | -119,616,000 | -134,055,000 | -146,119,000 | -144,600,000 | -130,321,000 | -123,338,000 | -98,208,000 | -107,288,000 | -97,642,000 | -107,863,000 | -91,166,000 | -74,252,000 | -54,620,000 | -34,912,000 | -25,962,000 | -17,477,000 | -15,268,000 | -23,664,000 | -27,387,000 | -24,205,000 |
yoy | -25.64% | 35.17% | -21.48% | -8.21% | 8.69% | 48.79% | 34.78% | 33.47% | 14.35% | 7.72% | 44.49% | 78.77% | 208.96% | 251.15% | 324.86% | 257.74% | 47.53% | -5.20% | -27.80% | ||||
qoq | -49.53% | 73.95% | -5.08% | -10.77% | -8.26% | 1.05% | 10.96% | 5.66% | 25.59% | -8.46% | 9.88% | -9.48% | 18.31% | 22.78% | 35.94% | 56.45% | 34.47% | 48.55% | 14.47% | -35.48% | -13.59% | 13.15% | |
interest income | 14,868,000 | 13,888,000 | 11,690,000 | 6,727,000 | 3,060,000 | 2,150,000 | 1,754,000 | 1,387,000 | 778,000 | 653,000 | 689,000 | 1,037,000 | 1,551,000 | 1,900,000 | 2,313,000 | 2,640,000 | 3,318,000 | 3,871,000 | 4,286,000 | 3,099,000 | 2,485,000 | 2,334,000 | 958,000 |
interest expense | -645,000 | -645,000 | -644,000 | -645,000 | -644,000 | -644,000 | -644,000 | -645,000 | -644,000 | -643,000 | -644,000 | -644,000 | -646,000 | -4,736,000 | -8,000 | -10,000 | -12,000 | -321,000 | -280,000 | -287,000 | -293,000 | -299,000 | -304,000 |
other income | -29,120,000 | -3,316,000 | 16,885,000 | 41,259,000 | -1,654,000 | 5,281,000 | -18,389,000 | 378,000 | -48,000 | 25,898,000 | -187,000 | -243,000 | -290,000 | 1,220,000 | 345,000 | 2,285,000 | -209,000 | -187,000 | 179,000 | -51,000 | 147,000 | 115,000 | 43,000 |
income before benefit from income taxes | -114,580,000 | -187,584,000 | -85,612,000 | -72,275,000 | -133,293,000 | -139,332,000 | -161,879,000 | -228,986,000 | -123,252,000 | -72,300,000 | -107,430,000 | -97,492,000 | -107,248,000 | -92,782,000 | -71,602,000 | -49,705,000 | -31,815,000 | -22,599,000 | -13,292,000 | -12,507,000 | -21,325,000 | -25,237,000 | -23,508,000 |
benefit from income taxes | 405,000 | -541,000 | 490,000 | 496,000 | 240,000 | 602,000 | 115,000 | 446,000 | -24,000 | 11,000 | 96,000 | 83,000 | 110,000 | 263,000 | 68,000 | 34,000 | 14,000 | -489,000 | -202,000 | -1,207,000 | 26,000 | 35,000 | |
net income | -114,985,000 | -187,043,000 | -86,102,000 | -72,771,000 | -133,533,000 | -139,934,000 | -161,994,000 | -229,432,000 | -123,228,000 | -72,311,000 | -107,526,000 | -97,575,000 | -107,358,000 | -93,045,000 | -71,670,000 | -49,739,000 | -31,829,000 | -22,110,000 | -13,090,000 | -11,300,000 | -21,351,000 | -25,272,000 | -23,508,000 |
yoy | -13.89% | 33.67% | -46.85% | -68.28% | 8.36% | 93.52% | 50.66% | 135.13% | 14.78% | -22.28% | 50.03% | 96.17% | 237.30% | 320.83% | 447.52% | 340.17% | 49.07% | -12.51% | -44.32% | ||||
qoq | -38.52% | 117.23% | 18.32% | -45.50% | -4.57% | -13.62% | -29.39% | 86.18% | 70.41% | -32.75% | 10.20% | -9.11% | 15.38% | 29.82% | 44.09% | 56.27% | 43.96% | 68.91% | 15.84% | -47.08% | -15.52% | 7.50% | |
net income per share | -0.94 | -1.62 | -0.73 | -0.67 | -1.3 | -1.37 | -1.58 | -2.25 | -1.21 | -0.89 | -1.06 | -0.96 | -1.09 | -0.94 | -0.78 | -0.57 | -0.29 | -0.28 | -0.14 | -0.13 | -0.3 | 2.07 | -1.94 |
weighted-average shares used for eps calculation | 121,712 | 111,988 | 117,736 | 108,808 | 102,663 | 102,178 | 102,289 | 102,047 | 101,853 | 101,314 | 101,420 | 101,172 | 100,955 | 97,504 | 99,554 | 96,011 | 94,382 | 90,597 | 93,303 | 89,036 | 85,935 | 30,403 | 12,582 |
fair value adjustments of noncontrolling interest liability | -99,785,000 | ||||||||||||||||||||||
adjustment of redeemable noncontrolling interest | -18,600,000 | -2,300,000 | -700,000 | -6,000,000 | -4,900,000 | 4,100,000 | |||||||||||||||||
net income attributable to guardant health, inc. common stockholders | -139,934,000 | -161,994,000 | -229,432,000 | -123,228,000 | -90,911,000 | -107,526,000 | -97,575,000 | -109,658,000 | -93,745,000 | -77,670,000 | -54,639,000 | -27,729,000 | -25,210,000 | -12,790,000 | -11,600,000 | -26,051,000 | -25,122,000 | -24,458,000 |